Advancing evidence-generating medicine
Osmind’s research is helping to set new standards for mental health interventions and improve patient outcomes. See how we work with research partners to generate real-world evidence to accelerate advances in mental health care.
Selected research projects
Prediction of treatment adherence to ketamine infusion therapy
Kane, Worley, Oldenkamp et al. (2023). Psychedelic Science.
CLEO: A Phase 2 Randomized Controlled Adjunctive Treatment Trial with CLE-100 Esketamine Tablet for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants, During The COVID-19 Pandemic
Fava, Berkowitz, Mathew et al. (2023). American Society of Clinical Psychopharmacology Annual Meeting.
Osmind Announces 2023 Community Advisory Board: Leading Mental Health Clinicians
A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings
McInnes, Qian, Gargeya et al. (2022). Journal of Affective Disorders.
REMS in Interventional Psychiatry: A Case Study in Innovation
Qian and MacMillan (2021). REMS Innovation Summit.
A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings
McInnes, Qian, Gargeya et al. (2021). Psychedelic Therapeutics and Drug Development Conference.
Let's transform mental health together
Click here to learn more about our research or to discuss collaboration opportunities.
